{
"id":"mk19_b_en_q002",
"number":2,
"bookId":"en",
"correctAnswer":"A",
"title":"Question 2",
"stimulus":[
{
"type":"p",
"hlId":"52e9c1",
"children":[
"A 46-year-old woman is evaluated for type 2 diabetes mellitus diagnosed 3 months ago. She also has hyperlipidemia, hypertension, and obesity. At the time of her diagnosis, her ",
{
"type":"reference-range-link",
"referenceRange":"Hemoglobin A1c, blood",
"children":[
"hemoglobin A",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"1c"
]
}
]
},
" value was 8.5% and BMI was 33. Metformin was initiated. During the past 3 months, she has lost 5.0 kg (11.0 lb). Medications are metformin, lisinopril, and simvastatin."
]
},
{
"type":"p",
"hlId":"49924a",
"children":[
"On physical examination, vital signs are within normal limits. BMI is 32. The remainder of the examination is unremarkable."
]
},
{
"type":"p",
"hlId":"6c5c33",
"children":[
"Today, her ",
{
"type":"reference-range-link",
"referenceRange":"Hemoglobin A1c, blood",
"children":[
"hemoglobin A",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"1c"
]
}
]
},
" measurement is 8%."
]
}
],
"prompt":[
" ",
{
"type":"p",
"hlId":"286317",
"children":[
"Which of the following is the most appropriate treatment to start next?"
]
},
" "
],
"options":[
{
"letter":"A",
"text":{
"__html":"Dulaglutide"
}
},
{
"letter":"B",
"text":{
"__html":"Glipizide"
}
},
{
"letter":"C",
"text":{
"__html":"Insulin"
}
},
{
"letter":"D",
"text":{
"__html":"Pioglitazone"
}
}
],
"keypoints":[
{
"type":"keypoint",
"hlId":"4362bf",
"children":[
"In young, otherwise healthy patients, the American Diabetes Association recommends a hemoglobin A",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"1c"
]
},
" target of less than 7% in most nonpregnant adults."
]
},
{
"type":"keypoint",
"hlId":"210386",
"children":[
"A glucagon-like peptide 1 receptor agonist or sodium-glucose cotransporter 2 inhibitor with demonstrated cardiovascular benefit is recommended in patients with type 2 diabetes and established atherosclerotic cardiovascular disease (ASCVD) or multiple risk factors for ASCVD to reduce the risk for major adverse cardiovascular events."
]
}
],
"exposition":[
{
"type":"p",
"hlId":"82640b",
"children":[
"The best treatment option for this patient is to add dulaglutide (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option A"
]
},
"). At the time of diagnosis, metformin was initiated, which is first-line pharmacologic therapy for the management of type 2 diabetes mellitus. Although she has made some progress with hemoglobin A",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"1c"
]
},
" reduction and weight loss, her glycemic target is still not at goal. In young, otherwise healthy patients, the American Diabetes Association recommends a hemoglobin A",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"1c"
]
},
" target of less than 7% in most nonpregnant adults, suggesting that an even more stringent target, less than 6.5%, may be appropriate for some patients if it can be achieved without significant hypoglycemia or adverse effects. Patients should be re-evaluated at 3-month intervals and treatment escalated with additional agents if the hemoglobin A",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"1c"
]
},
" remains above goal. In patients with type 2 diabetes mellitus and established atherosclerotic cardiovascular disease (ASCVD) or multiple risk factors for ASCVD, a glucagon-like peptide 1 receptor agonist (GLP-1 RA) or sodium-glucose cotransporter 2 (SGLT2) inhibitor with demonstrated cardiovascular benefit is recommended to reduce the risk for major adverse cardiovascular events, independent of hemoglobin A",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"1c"
]
},
" lowering. This patient has multiple risk factors for ASCVD (hypertension, dyslipidemia, obesity). In addition, GLP-1 RAs are associated with weight loss, which would be beneficial for this patient with obesity. Dulaglutide is a GLP-1 RA with proven cardiovascular benefit."
]
},
{
"type":"p",
"hlId":"02b2f1",
"children":[
"Glipizide (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option B"
]
},
") is a sulfonylurea and stimulates insulin secretion. It is associated with weight gain and has no ASCVD benefits."
]
},
{
"type":"p",
"hlId":"809a7b",
"children":[
"In most patients who need the greater glucose-lowering effect of an injectable medication, GLP-1 RAs are preferred to insulin (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option C"
]
},
"). Insulin administration is not associated with the ASCVD benefits of a GLP-1 RA and may also cause weight gain."
]
},
{
"type":"p",
"hlId":"48ea71",
"children":[
"Pioglitazone (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option D"
]
},
"), a thiazolidinedione, increases peripheral uptake of glucose. Although pioglitazone can possibly decrease cardiovascular disease events, it is associated with weight gain, which is undesirable in this patient with obesity."
]
}
],
"relatedSection":"mk19_b_en_s1_1_4_5_2",
"objective":{
"__html":"Treat type 2 diabetes mellitus in a patient with atherosclerotic cardiovascular disease risk factors."
},
"references":[
[
"Das SR, Everett BM, Birtcher KK, et al. 2018 ACC expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. J Am Coll Cardiol. 2018;72:3200-3223. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/30497881",
"target":"_blank"
},
"children":[
"PMID: 30497881"
]
},
" doi:10.1016/j.jacc.2018.09.020"
]
],
"hospitalist":false,
"hvc":false,
"peerComparison":{
"A":85,
"B":7,
"C":4,
"D":4,
"E":0
},
"hlIds":[
"52e9c1",
"49924a",
"6c5c33",
"286317",
"4362bf",
"210386",
"82640b",
"02b2f1",
"809a7b",
"48ea71"
]
}